A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (NCT06585774)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (AXemplify-357)
🩺 Plain-English Summary (8th-Grade Level)
This study will be conducted to compare the efficacy of axatilimab versus placebo in combination with corticosteroids as initial treatment for moderate or severe chronic graft-versus-host disease (cGVHD).
Who can join: Review the eligibility criteria below.
Location: University of Alabama Birmingham — Birmingham, Alabama
Age range: 12 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (126 Sites)
Showing the first 25 of 126 sites.
- University of Alabama Birmingham — Birmingham, Alabama
- University of Arizona Cancer Center-Out Pt. — Tucson, Arizona
- City of Hope Medical Center — Duarte, California
- University of California San Diego Medical Center, Moores Cancer Center — La Jolla, California
- University of Southern California — Los Angeles, California
- UCSF — San Francisco, California
- Colorado Blood Cancer Institute — Denver, Colorado
- Childrens National Hospital — Washington D.C., District of Columbia
- Miami Cancer Institute — Miami, Florida
- Orlando Health Cancer Institute Downtown Orlando — Orlando, Florida
- Memorial Cancer Institute — Pembroke Pines, Florida
- Emory University-Winship Cancer Institute — Atlanta, Georgia
- Northwestern Memorial Hospital — Chicago, Illinois
- University of Illinois — Chicago, Illinois
- The University of Kansas Cancer Center — Kansas City, Kansas
- John Hopkins Hospital — Baltimore, Maryland
- Massachusetts General Hospital — Boston, Massachusetts
- Dana Farber Cancer Institute — Boston, Massachusetts
- University of Michigan — Ann Arbor, Michigan
- Henry Ford Hospital — Detroit, Michigan
- Corewell Health Hematology Oncology — Grand Rapids, Michigan
- Hackensack University Medical Center — Hackensack, New Jersey
- Rutgers Cancer Institute of Nj — New Brunswick, New Jersey
- University of Rochester Medical Center — Rochester, New York
- Stony Brook University Medical Center — Stony Brook, New York
📞 Contact the Study Coordinator
Phone: (855) 463-3463
Email: medinfo@incyte.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Chronic Graft-versus-host-disease
- A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease — Phoenix, Arizona
- A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256) — Duarte, California
- A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD) — Birmingham, Alabama
Explore by condition: All Chronic Graft-versus-host-disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.